Global Gastric Cancer Market 2016 - How Will Eli Lilly Look to Maintain Cyramza's First-to-Market Advantage? - Research and Markets

DUBLIN, August 10, 2016 /PRNewswire/ --

Research and Markets has announced the addition of the "Gastric Cancer" report to their offering.

Pipeline therapies will look to fulfil many areas of high unmet need left by the lack of targeted therapies approved for the treatment of gastric cancer.

This report addresses the following questions:

- What impact will the PD-1/PD-L1 inhibitor class of drugs have on the gastric cancer market?

- How will pipeline immunotherapies be positioned in the gastric cancer treatment space?

- Which targeted therapies are expected to experience the greatest growth over the forecast period?

- How will Eli Lilly look to maintain Cyramza's first-to-market advantage?

- What are the key drivers of the rapidly expanding gastric cancer market?

Key Topics Covered:

FORECAST: GASTRIC CANCER

- Avelumab

- BBI

- (napabucasin)

- Cyramza (ramucirumab)

- GS-57

- Herceptin (trastuzumab)

- Keytruda (pembrolizumab)

- Lynparza (olaparib)

- Nimotuzumab

- Opdivo (nivolumab)

- Perjeta (pertuzumab)

TREATMENT: GASTRIC CANCER 

- Disease Definition and Diagnosis

- Patient Segmentation

- Country Treatment Trees

- Current Treatment Options

- Prescribing Trends

EPIDEMIOLOGY: GASTRIC CANCER IN THE US, JAPAN, AND 5EU

- Forecast

- Epidemiologist Insight

- Strengths and Limitations

MARKETED DRUGS: GASTRIC CANCER

- Product profile: Cyramza

- Product profile: Herceptin

PIPELINE: GASTRIC CANCER

- Product profile (late stage): BBI6

- Product profile (late stage): GS-57

- Product profile (late stage): Keytruda

- Product profile (late stage): Lynparza

- Product profile (late stage): Opdivo

- Product profile (late stage): Perjeta

- Product profile (late stage): avelumab

- Product profile (late stage): nimotuzumab

For more information visit http://www.researchandmarkets.com/research/j8lnrz/gastric_cancer

Media Contact:

Research and Markets

Laura Wood, Senior Manager

[email protected]

For E.S.T Office Hours Call +1-917-300-0470

For U.S./CAN Toll Free Call +1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907

Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

Related Links

http://www.researchandmarkets.com